Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion

Next Previous
Trial Profile

A Study to Learn How Well the Drug Larotrectinib Works in Adults With Different Solid Cancers With a Change in the Genes Called NTRK Fusion

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Larotrectinib (Primary)
  • Indications Advanced breast cancer; Appendiceal cancer; Biliary cancer; Carcinoma; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Duodenal cancer; Gastric cancer; Glioma; Head and neck cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Meningeal carcinomatosis; Neuroblastoma; Neuroepithelial neoplasms; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Salivary gland cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NAVIGATE
  • Sponsors Bayer; Loxo Oncology

Most Recent Events

  • 13 May 2025 Planned End Date changed from 30 Nov 2025 to 31 Oct 2025.
  • 10 Apr 2025 According to a Bayer media release,U.S. Food and Drug Administration (FDA) has granted full approval for VITRAKVI(larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion based on on data from LOXO-TRK-14001,SCOUT and NAVIGATE trial
  • 12 Mar 2025 Planned End Date changed from 31 Oct 2025 to 30 Nov 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top